000168067 001__ 168067
000168067 005__ 20260202145621.0
000168067 0247_ $$2doi$$a10.1016/j.numecd.2010.10.011
000168067 0248_ $$2sideral$$a131346
000168067 037__ $$aART-2011-131346
000168067 041__ $$aeng
000168067 100__ $$0(orcid)0000-0001-9142-0737$$aJarauta, E.
000168067 245__ $$aCarotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia
000168067 260__ $$c2011
000168067 5203_ $$aBackground and Aims: Familial hypercholesterolaemia (FH) and familial combined hyperlipidaemia (FCH) are common atherogenic disorders with great variability in cardiovascular disease (CVD). No direct atherosclerosis burden comparisons have been performed between FH and FCH in relation to lipoprotein particle distribution.
Methods and Results: Risk factors and three measures of carotid intima-media thickness (IMT) in both sides were determined in 572 FH, 250 FCH and 200 controls. Lipoproteins were assessed by nuclear magnetic resonance (NMR) spectroscopy. Compared with controls, IMT measures were increased in FH and FCH. FCH had the highest adjusted mean–maximum IMT. FH had twice low-density lipoprotein (LDL) particles than controls, but similar LDL subclass size and distribution. FCH subjects also had increased LDL particles and the highest number of small LDL (1519 ± 731 nmol l−1 vs. 887 ± 784 nmol l−1 in FH and 545 ± 409 nmol l−1 in controls). Age, gender, cholesterol/high-density lipoprotein (HDL) ratio, smoking and systolic blood pressure were independently associated with IMT in FH (r2 = 0.38). The same variables, except cholesterol/HDL ratio, were associated with IMT in FCH (r2 = 0.40). Among NMR lipoproteins, only VLDL and chylomicrons increased IMT prediction in FCH by 0.8%.
Conclusion: FH and FCH subjects show increased carotid atherosclerosis in relation to classical risk factors. Lipoprotein subclasses do not substantially contribute to IMT variability.
000168067 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000168067 590__ $$a3.731$$b2011
000168067 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b27 / 117 = 0.231$$c2011$$dQ1$$eT1
000168067 591__ $$aNUTRITION & DIETETICS$$b13 / 73 = 0.178$$c2011$$dQ1$$eT1
000168067 591__ $$aENDOCRINOLOGY & METABOLISM$$b36 / 122 = 0.295$$c2011$$dQ2$$eT1
000168067 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000168067 700__ $$0(orcid)0000-0001-6650-8294$$aMateo-Gallego, R.$$uUniversidad de Zaragoza
000168067 700__ $$aGilabert, R.
000168067 700__ $$aPlana, N.
000168067 700__ $$aJunyent, M.
000168067 700__ $$ade Groot, E.
000168067 700__ $$aCenarro, A.$$uUniversidad de Zaragoza
000168067 700__ $$aMasana, L.
000168067 700__ $$aRos, E.
000168067 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000168067 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000168067 773__ $$g22, 7 (2011), 591-597$$pNMCD, Nutr. Metab. Cardiovasc. Dis.$$tNutrition, Metabolism and Cardiovascular Diseases$$x0939-4753
000168067 8564_ $$s219102$$uhttps://zaguan.unizar.es/record/168067/files/texto_completo.pdf$$yVersión publicada
000168067 8564_ $$s2025141$$uhttps://zaguan.unizar.es/record/168067/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000168067 909CO $$ooai:zaguan.unizar.es:168067$$particulos$$pdriver
000168067 951__ $$a2026-02-02-14:49:04
000168067 980__ $$aARTICLE